(RTTNews) - Insulet (PODD) announced it has received FDA 510(k) clearance for significant enhancements to the Omnipod 5 Automated Insulin Delivery System. The new 100 mg/dL Target Glucose expands ...
Zacks Investment Research on MSN
PODD stock benefits from FDA approval of Omnipod 5's enhancements
Insulet Corporation PODD recently received FDA 510(k) clearance for significant enhancements to the Omnipod 5 Automated Insulin Delivery System. These updates to the Omnipod 5 algorithm set a new ...
Insulet Corporation PODD recently made its Omnipod 5 Automated Insulin Delivery (“AID”) System commercially available in Australia. Omnipod 5 is available with Dexcom G6 and G7 continuous glucose ...
New 100 mg/dL Target Glucose setting offers more customization and tighter glucose management. Enhanced algorithm helps users remain in Automated Mode to improve the user experience. Most requested ...
The tubeless Omnipod 5 automated insulin delivery system, launched in the United Kingdom in 2023, was associated with improved time in range (TIR) at 1 year, with no increase in time below range and ...
The expanded approval for the Omnipod 5 system now allows automated insulin delivery (AID) for adults with type 2 diabetes, offering a new option for better glucose management without daily injections ...
Mar. 18, 2025 6:05 AM ETInsulet Corporation (PODD) “Bringing our life-changing flagship Omnipod 5 to people living with diabetes in these four new countries is both incredibly exciting and meaningful, ...
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today made ...
Insulet Corporation (NASDAQ:PODD) reported second-quarter adjusted earnings of $1.17 per share, beating the consensus of 92 cents. PODD shares are rallying today. Track live prices here. The automated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback